• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Implants

Battery-free pacemaker successfully powers the heart

June 12, 2017 By Danielle Kirsh

A wireless, battery-free pacemaker has shown success in powering the heart in pig models, according to researchers from Rice University and Texas Heart Institute. The pacemaker, designed by lead researcher Aydin Babakhani, gets its energy wirelessly from radio frequency radiation that gets transmitted wirelessly from an external battery pack from a few centimeters away. Get […]

Filed Under: Cardiovascular, Featured, Implants Tagged With: cardiology, medtech, pacemakers, Rice University, University of Connecticut

Living Cell Technologies NTCell meets primary endpoint in Phase I/IIa Parkinson’s trial

June 6, 2017 By Sarah Faulkner

Living Cell Technologies

Living Cell Technologies (ASX:LCT) touted data today showing its NTCell cell therapy is safe 130 weeks after treatment in a Phase I/IIa Parkinson’s trial. The study’s primary endpoint was safety. The trial, which enrolled and treated 4 patients, involved implanting 40 NTCell capsules into 1 side of the brain. The company reported that treatment with […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Neurological Tagged With: livingcelltechnologies

BioCorRx partners with virtual reality center for naltrexone implant study

June 1, 2017 By Sarah Faulkner

BioCorRx

BioCorRx (OTC:BICX) said today that it partnered with the Virtual Reality Medical Center to conduct a study on the company’s long-lasting naltrexone implant. BioCorRx’s recovery program consists of a long-lasting implant that delivers an opioid antagonist, naltrexone, which reduces physical cravings for alcohol and opioids. The recovery service also has a counseling program specifically designed […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Wall Street Beat Tagged With: BioCorRx

Intersect ENT updates on Sinuva steroid-releasing sinus implant

May 22, 2017 By Sarah Faulkner

Intersect ENT

Intersect ENT (NSDQ:XENT) said today that the FDA is slated to make a decision on its new drug application for the Sinuva steroid-releasing sinus implant by January 7, 2018. The Sinuva implant, which was previously called the Resolve implant, is placed during an in-office doctors appointment and is designed to be a treatment option for […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Otolaryngology Ear, Nose & Throat, Wall Street Beat Tagged With: Intersect ENT Inc.

Infertility: There could be a 3D printing solution

May 16, 2017 By Chris Newmarker

New Northwestern University research offers a potential 3D printing solution for women’s infertility – providing hope for cancer survivors who want to start families. The Northwestern researchers successfully 3D printed a bioprosthetic mouse ovary that ovulated when implanted inside a live mouse. Mice with the bioprosthetic ovaries were able to give birth to live pups, […]

Filed Under: Featured, Hydrogels, Implants, Regenerative Medicine, Women's Health Tagged With: 3D printing, bioprinting, infertility, Northwestern University

NanoMedical Systems raises $4.1m

May 12, 2017 By Sarah Faulkner

NanoMedical Systems raised $4.1 million in a new round of financing, according to a regulatory filing. The Delaware-based company offered equity and warrants to the 46 investors that contributed to the round. The company did not disclose how it plans to use its newly-acquired funds. No money from the round is slated to compensate sales […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Implants Tagged With: nanomedicalsystems

Study: pSivida’s Durasert lessens recurrence of uveitis through 12 months

May 9, 2017 By Sarah Faulkner

pSivida

pSivida (NSDQ:PSDV) touted 1-year follow-up data yesterday for the company’s Durasert 3-year treatment of posterior segment uveitis. The data, which was presented at the Association for Research in Vision and Ophthalmology annual meeting, is from pSivida’s 1st phase III trial. The data showed that the 3-year uveitis implant significantly reduced the recurrence of posterior segment uveitis […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: pSivida Corp.

Systemic therapy beats Bausch & Lomb implant in NIH uveitis study

May 8, 2017 By Sarah Faulkner

National Eye Institute

Systemic therapy of corticosteroids and immunosuppressants better preserved vision in patients with uveitis compared to Bausch & Lomb‘s long-lasting corticosteroid intraocular implant in a clinical trial supported by the National Eye Institute, a branch of the National Institutes of Health. In 7 years, visual acuity remained stable in patients receiving systemic therapy and declined by […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Wall Street Beat Tagged With: bausch&lomb, National Institutes of Health

Glaukos shares tumble despite Q1 beat

May 4, 2017 By Sarah Faulkner

Glaukos logo

Shares in Glaukos (NYSE:GKOS) fell -10% today after the ophthalmic medtech company beat expectations on Wall Street with its 1st quarter results. The San Clemente, Calif.-based company posted profits of $878,000, or 2¢ per share, on sales of $35.9 million for the 3 months ended March 31, for bottom-line loss of -2% on sales growth of […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Glaukos Corp.

Intersect ENT beats Q1 earnings, rev forecast

May 3, 2017 By Sarah Faulkner

Intersect ENT

Shares in Intersect ENT (NSDQ:XENT) fell slightly yesterday after the drug-device maker met expectations on Wall Street with its 1st quarter results. The Menlo Park, Calif.-based company posted a loss of  -$6.8 million, or -23¢ per share, on sales of $20.5 million for the 3 months ended March 31, for bottom-line growth of 20% on sales growth of 22.8% […]

Filed Under: Drug-Device Combinations, Featured, Implants, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Intersect ENT Inc.

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 7
  • Go to page 8
  • Go to page 9
  • Go to page 10
  • Go to page 11
  • Go to page 12
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS